High Performance Antenna System in MIMO Configuration for 5G Wireless Communications Over Sub-6 GHz Spectrum

This paper presents a high-performance multiple input and multiple output (MIMO) antenna comprising 2 × 2 configuration of radiating elements that is designed for sub-6 GHz applications. The proposed MIMO antenna employs four identical radiating elements. High isolation between the radiating elements and therefore reduced mutual coupling is achieved by spatially arranging the radiating elements in an orthogonal configuration. Also, a novel frequency selective surface (FSS) was employed to increase the gain of the MIMO antenna over a wide bandwidth from 3 to 6 GHz. This was achieved by locating the FSS above the antenna at a certain height. The FSS essentially enhanced the antenna's directivity, reduced back lobe radiation and mutual coupling. The antenna was fabricated on a standard Rogers RT Duroid 5880 dielectric substrate with a 0.8 mm thickness. The overall dimension of the MIMO antenna is 50 × 50 × 12.5 mm3 and it operates from 3.8 to 6 GHz, which corresponds to a fractional bandwidth of 41%. The proposed MIMO antenna has a measured peak gain of 4.8 dBi and inter radiation element isolation >20 dB. Its envelope correlation coefficient is <0.1 and diversity gain >9.9 (dB). These characteristics make the proposed MIMO antenna system suitable for 5G communication systems

A double-blind placebo controlled trial into the impacts of HMB supplementation and exercise on free-living muscle protein synthesis, muscle mass and function, in older adults

Age-related sarcopenia and dynapenia are associated with frailty and metabolic diseases. Resistance exercise training (RET) adjuvant to evidence-based nutritional intervention(s) have been shown as mitigating strategies. Given that \u3b2-hydroxy-\u3b2-methyl-butyrate (HMB) supplementation during RET improves lean body mass in younger humans, and that we have shown that HMB acutely stimulates muscle protein synthesis (MPS) and inhibits breakdown; we hypothesized that chronic supplementation of HMB free acid (HMB-FA) would enhance MPS and muscle mass/function in response to RET in older people. We recruited 16 healthy older men (Placebo (PLA): 68.5 \ub1 1.0 y, HMB-FA: 67.8 \ub1 1.15 y) for a randomised double-blind-placebo controlled trial (HMB-FA 3 7 1 g/day vs. PLA) involving a 6-week unilateral progressive RET regime (6 7 8 repetitions, 75% 1-RM, 3 \ub7 wk 121). Deuterium oxide (D2O) dosing was performed over the first two weeks (0\u20132 wk) and last two weeks (4\u20136 wk) with bilateral vastus lateralis (VL) biopsies at 0\u20132 and 4\u20136 wk (each time 75 \ub1 2 min after a single bout of resistance exercise (RE)) for quantification of early and later MPS responses and post-RE myogenic gene expression. Thigh lean mass (TLM) was measured by DXA, VL thickness and architecture (fibre length and pennation angle) by ultrasound at 0/3/6 wk, and strength by knee extensor 1-RM testing and MVC by isokinetic dynamometry (approx. every 10 days). RET induced strength increases (1-RM) in the exercised leg of both groups (398 \ub1 22N to 499 \ub1 30N HMB-FA vs. 396 \ub1 29N to 510 \ub1 43N PLA (both P < 0.05)). In addition, maximal voluntary contraction (MVC) also increased (179 \ub1 12 Nm to 203 \ub1 12 Nm HMB-FA vs. 185 \ub1 10 Nm to 217 \ub1 11 Nm PLA (both P < 0.05); with no group differences. VL muscle thickness increased significantly in the exercised leg in both groups, with no group differences. TLM (by DXA) rose to significance only in the HMB-FA group (by 5.8%\u20135734 \ub1 245 g p = 0.015 vs. 3.0% to 5644 \ub1 323 g P = 0.06 in PLA). MPS remained unchanged in the untrained legs (UT) 0\u20132 weeks being 1.06 \ub1 0.08%.d 121 (HMB-FA) and 1.14 \ub1 0.09%.d 121 (PLA), the trained legs (T) exhibited increased MPS in the HMB-FA group only at 0\u20132-weeks (1.39 \ub1 0.10%.d 121, P < 0.05) compared with UT: but was not different at 4\u20136-weeks: 1.26 \ub1 0.05%.d 121. However, there were no significant differences in MPS between the HMB-FA and PLA groups at any given time point and no significant treatment interaction observed. We also observed significant inductions of c-Myc gene expression following each acute RE bout, with no group differences. Further, there were no changes in any other muscle atrophy/hypertrophy or myogenic transcription factor genes we measured. RET with adjuvant HMB-FA supplements in free-living healthy older men did not enhance muscle strength or mass greater than that of RET alone (PLA). That said, only HMB-FA increased TLM, supported by early increases in chronic MPS. As such, chronic HMB-FA supplementation may result in long term benefits in older males, however longer and larger studies may be needed to fully determine the potential effects of HMB-FA supplementation; translating to any functional benefit

Subsurface structural investigation based on seismic data of the north-eastern Potwar basin, Pakistan

1258-1268The north-eastern Potwar is present in the foothills of Himalayas on the northern boundary of the Indian Plate and is filled by the Infra-Cambrian to Pliocene sedimentation. The area is affected by the regional structures of the Potwar and the Salt-Range Structures, such as the North Potwar Deformed Zone (NPDZ), the Soan Syncline, the Main Boundary Thrust (MBT) and the Jhelum Fault. Due to complex tectonic-structural framework, it is extremely significant to understand the subsurface structural mechanisms for further hydrocarbons exploration. The 2D seismic data was acquired in the NE-Potwar in the Rawat area is used for this purpose. The current study helps to present rigorous and mechanically feasible structure understanding of the Rawat and associated local structures of the area in the context of the Sub-Himalayas. The study area mainly comprises on the eastern Potwar with tight anticlines and wide synclines with associated thrusts showing collisional regime of the Himalayan Fold and the thrust belt. The structural interpretation and restoration of paleo-section provide a mechanically feasible model for the Rawat area. The interpretation of seismic data shows that this area is associated with conjugate faults and a triangle zone. The results of this study help us to develop understanding in geological history, structural overprint and future leads for hydrocarbons in this geological province

Defective extracellular matrix remodeling in brown adipose tissue is associated with fibro-inflammation and reduced diet-induced thermogenesis.

The relevance of extracellular matrix (ECM) remodeling is reported in white adipose tissue (AT) and obesity-related dysfunctions, but little is known about the importance of ECM remodeling in brown AT (BAT) function. Here, we show that a time course of high-fat diet (HFD) feeding progressively impairs diet-induced thermogenesis concomitantly with the development of fibro-inflammation in BAT. Higher markers of fibro-inflammation are associated with lower cold-induced BAT activity in humans. Similarly, when mice are housed at thermoneutrality, inactivated BAT features fibro-inflammation. We validate the pathophysiological relevance of BAT ECM remodeling in response to temperature challenges and HFD using a model of a primary defect in the collagen turnover mediated by partial ablation of the Pepd prolidase. Pepd-heterozygous mice display exacerbated dysfunction and BAT fibro-inflammation at thermoneutrality and in HFD. Our findings show the relevance of ECM remodeling in BAT activation and provide a mechanism for BAT dysfunction in obesity

The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1

CYP2D6 plays a major role in the metabolism of tamoxifen, and polymorphism of Pglycoprotein has been associated with resistance of many drug therapies. This study investigates the clinical impact of genetic variants of CYP2D6 and ABCB1 in breast cancer patients treated with tamoxifen. Blood samples from 95 breast cancer patients treated with tamoxifen were collected and genotyped for CYP2D6 and ABCB1 variants using allele-specific PCR method. Recurrence risks were calculated using Kaplan–Meier analysis and compared using the log-rank test. Patients carrying CYP2D6*10/*10 and heterozygous null allele (IM) showed higher risks of developing recurrence and metastasis (OR 13.14; 95% CI 1.57–109.94; P=0.004) than patients with CYP2D6*1/*1 and *1/*10 genotypes. Patients with homozygous CC genotypes of ABCB1 C3435T showed a shorter time to recurrence. Patients who were CYP2D6 IM and homozygous CC genotype of C3435T have statistically significant higher risks of recurrence (P=0.002). Similarly, median time to recurrence in these patients was only 12 months (95% CI=0.79–23.2) compared to those without this combination which was 48 months (95% CI=14.7–81.2). Patients with CYP2D6 IM and homozygous CC genotype of ABCB1 C3435T have shorter times to recurrence. The results confirmed the findings of previous studies and support FDA recommendation to perform pre-genotyping in patients before the choice of therapy is determined in breast cancer patients

Novel C8orf37 mutations cause retinitis pigmentosa in consanguineous families of Pakistani origin

Purpose: To investigate the molecular basis of retinitis pigmentosa in two consanguineous families of Pakistani origin with multiple affected members. Methods: Homozygosity mapping and Sanger sequencing of candidate genes were performed in one family while the other was analyzed with whole exome next-generation sequencing. A minigene splicing assay was used to confirm the splicing defects. Results: In family MA48, a novel homozygous nucleotide substitution in C8orf37, c.244–2A>C, that disrupted the consensus splice acceptor site of exon 3 was found. The minigene splicing assay revealed that this mutation activated a cryptic splice site within exon 3, causing a 22 bp deletion in the transcript that is predicted to lead to a frameshift followed by premature protein truncation. In family MA13, a novel homozygous null mutation in C8orf37, c.555G>A, p.W185*, was identified. Both mutations segregated with the disease phenotype as expected in a recessive manner and were absent in 8,244 unrelated individuals of South Asian origin. Conclusions: In this report, we describe C8orf37 mutations that cause retinal dystrophy in two families of Pakistani origin, contributing further data on the phenotype and the spectrum of mutations in this form of retinitis pigmentosa

Unmodified Titanium Dioxide Nanoparticles as a potential contrast agent in photon emission computed tomography

Highly crystalline titanium dioxide nanoparticles (TiO2 -NPs) are synthesized via a simple hydrothermal technique. After structural and compositional analysis, the as-synthesized unmodified TiO2 -NPs are tested for improvement in two modes of kilovoltage radiation therapy and singlephoton emission computed tomography (SPECT)/computed tomography (CT). Our results show that the unmodified TiO2 -NPs provide an observable enhancement in CT scan image contrast ranging from 0 ± 3 HU (without NPs) to 283.7 ± 3 HU (0.23 g/mL). TiO2 -NPs has excellent biocompatibility, selective uptake at target sites, and reduced toxicity. The unmodified TiO2 -NPs as a contrast agent can significantly improve the existing methods of diagnosing and treating cancer

Structural, optical, and antibacterial efficacy of pure and zinc-doped copper oxide against Pathogenic bacteria

Copper oxide and Zinc (Zn)-doped Copper oxide nanostructures (CuO-NSs) are successfully synthesized by using a hydrothermal technique. The as-obtained pure and Zn-doped CuONSs were tested to study the effect of doping in CuO on structural, optical, and antibacterial properties. The band gap of the nanostructures is calculated by using the Tauc plot. Our results have shown that the band gap of CuO reduces with the addition of Zinc. Optimization of processing conditions and concentration of precursors leads to the formation of pine needles and sea urchinlike nanostructures. The antibacterial properties of obtained Zn-doped CuO-NSs are observed against Gram-negative (Pseudomonas aeruginosa, Klebsiella pneumonia, Escherichia coli) and Gram-positive (Staphylococcus aureus) bacteria via the agar well diffusion method. Zn doped s are found to have more effective bacterial resistance than pure CuO. The improved antibacterial activity is attributed to the reactive oxygen species (ROS) generation

Autologous stem cell transplantation with low-dose cyclophosphamide to improve mucosal healing in adults with refractory Crohn's disease: the ASTIClite RCT

Some text in this abstract has been reproduced from Lindsay J, Din S, Hawkey C, Hind D, Irving P, Lobo A, et al. OFR-9 An RCT of autologous stem-cell transplantation in treatment refractory Crohn’s disease (low-intensity therapy evaluation): ASTIClite. Gut 2021;70(Suppl. 4):A4. Background Treatment-refractory Crohn’s disease is characterised by chronic symptoms, poor quality of life and high costs to the NHS, and through days of work lost by patients. A previous trial of autologous haematopoietic stem cell transplant (HSCT) failed its end point of medication-free clinical remission for 3 months with no evidence of disease activity, and reported high toxicity. Subsequent studies suggest that HSCT achieves complete mucosal healing in 50% of patients, and that toxicity likely relates to the cyclophosphamide dose. Objectives The primary objective was to assess the efficacy of HSCTlite (HSCT with low-dose cyclophosphamide) compared with standard care for inducing regression of intestinal ulceration in patients with refractory Crohn’s disease at week 48. Secondary objectives included the assessment of disease activity, quality of life and regimen safety. Mechanistic objectives included immune reconstitution after HSCTlite. Design Two-arm, parallel-group randomised controlled trial with a 2 : 1 (intervention : control) allocation ratio. Setting Nine NHS trusts (eight trusts were recruitment sites; one trust was a treatment-only site). Participants Adults with treatment-refractory Crohn’s disease, for whom surgery was inappropriate or who had declined surgery. Interventions The intervention treatment was HSCTlite using cyclophosphamide, and the control was any current available treatment for Crohn’s disease, apart from stem cell transplantation. Main outcomes The primary outcome was treatment success at week 48 [mucosal healing (Simple Endoscopic Score for Crohn’s Disease ulcer subscore of 0) without surgery or death], assessed by central readers blinded to allocation and timing of assessment. Key secondary outcomes were clinical remission, Simple Endoscopic Score for Crohn’s Disease scores at week 48, change in Crohn’s Disease Activity Index scores and safety. Results The trial was halted owing to Suspected unexpected serious adverse events that took place after randomising 23 patients (HSCTlite arm, n = 13; usual-care arm, n = 10). Ten out of the 13 patients randomised to the HSCTlite arm received the intervention and nine (one death) reached the 48-week follow-up. In the usual-care arm 9 out of the 10 patients randomised reached the 48-week follow-up (one ineligible). The primary outcome was available for 7 out of 10 HSCTlite patients (including the patient who died) and six out of nine usual-care patients. Absence of endoscopic ulceration without surgery or death was reported in three out of seven (43%) HSCTlite patients, compared with zero out of six (0%) usual-care patients. Centrally read Simple Endoscopic Score for Crohn’s Disease scores [mean (standard deviation)] were 10.8 (6.3) and 10.0 (6.1) at baseline, compared with 2.8 (2.9) and 18.7 (9.1) at week 48, in the HSCT and usual-care arms, respectively. Clinical remission (Crohn’s Disease Activity Index scores of < 150) occurred in 57% and 17% of patients in the HSCTlite and usual-care arms, respectively, at week 48. Serious adverse events were more frequent in the HSCTlite arm [38 in 13 (100%) patients] than in the usual-care arm [16 in 4 (40%) patients]. Nine suspected unexpected serious adverse reactions were reported in six HSCTlite patients, including three cases of delayed renal failure due to proven thrombotic microangiopathy. Two HSCTlite patients died. Conclusions Within the limitations of reduced patient recruitment and numbers of patients assessed, HSCTlite meaningfully reduced endoscopic disease activity, with three patients experiencing resolution of ulceration. Suspected unexpected serious adverse reactions, particularly relating to thrombotic microangiopathy, make this regimen unsuitable for future clinical use. Limitations The early trial closure prevented complete recruitment, and the impact of the coronavirus pandemic prevented completion of some study investigations. Small participant numbers meant analysis could only be descriptive. Future work Owing to undetermined aetiology of thrombotic microangiopathy, further trials of HSCTlite in this population are not considered appropriate. Priorities should be to determine optimal treatment strategies for patients with refractory Crohn’s disease, including those with a stoma or multiple previous resections